Logotype for Repligen Corporation

Repligen (RGEN) Q2 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Repligen Corporation

Q2 2025 earnings summary

8 Jul, 2026

Executive summary

  • Q2 2025 revenue reached $182.4 million, up 15% year-over-year and 17% organic non-COVID growth, driven by broad-based demand across all regions and product lines, with strong contributions from Chromatography, Analytics, and recent acquisitions.

  • Orders grew over 20% year-over-year, marking the eighth consecutive quarter of orders exceeding non-COVID revenue and the fifth of sequential order growth.

  • Biopharma and CDMO revenues grew 20% year-over-year, with capital equipment and consumables leading growth.

  • Net income for Q2 2025 was $14.9 million, up from $5.7 million in Q2 2024, with GAAP EPS at $0.26 and adjusted EPS at $0.37.

  • Two acquisitions completed: 908 Devices PAT Portfolio in March 2025 and Tantti Laboratory Inc. in December 2024, strengthening product offerings and new modality capabilities.

Financial highlights

  • Q2 2025 revenue: $182.4 million, up 14.8% year-over-year; adjusted gross margin was 51.1%, flat year-over-year, while GAAP gross margin was 50.0%, down from 51.3%.

  • Adjusted income from operations was $22 million, up 8% year-over-year; adjusted operating margin was 12%, down 80 bps due to mix and acquisition headwinds.

  • Adjusted EBITDA margin was 17.6%, flat year-over-year; adjusted net income was $21 million, down $1 million year-over-year.

  • Cash and cash equivalents at June 30, 2025, were $709 million, down from $757 million at year-end 2024.

  • Working capital at June 30, 2025, was $934 million, a decrease from $939 million at year-end 2024.

Outlook and guidance

  • FY 2025 revenue guidance raised to $715–$735 million, representing 12.5%–15.5% organic non-COVID growth; organic revenue growth midpoint increased to 10.5%–13.5%.

  • Adjusted EPS guidance raised to $1.65–$1.72, representing 5%–9% growth; GAAP EPS guidance is $0.85–$0.92.

  • Adjusted gross margin expected at 52%–53% for the year; adjusted operating margin guidance at 13.5%–14.5%.

  • CapEx expected to be down 20%–25% versus 2024, returning to pre-COVID levels.

  • Guidance reflects a 1% FX tailwind and a ~1% headwind from new modalities.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Repligen